Desferal was purchased from Novartis Pharma (Schweiz AG, Swizerland). Cisplatin and tert-Butylhydroquinone (TBHQ), an activator of Nrf2 [41 (link)], were obtained from Aladdin (Aladdin industrial, Fengxian, Shanghai, China). Brusatol, an inhibitor of Nrf2 [29 (link)], was purchased from Rongbai (Shanghai, China). Fecl3 was obtained from Sinopharm Chemical Reagent Co. Ltd (Shanghai, China). The SYBR premix ExTaq II system was purchased from Takara (Otsu, Japan). Small interfering RNA of SLC40A1 and its nonspecific control were purchased from Riobobio (Guangzhou, China), and the siRNA sequences were shown in Table 1. pCDH-CMV-MCS-EF1-copGFP-Nrf2 plasmid, pLenR-shNrf2 plasmid and their specific control plasmid were purchased from Ivabio (Shanghai, China). Renilla plasmid was kindly provided by Pro. Ming Yao (State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China). DMSO was purchased from Sigma (St. Louis, MO), which was used as solvent for Desferal, TBHQ, Fecl3.
Free full text: Click here